Similar articles for PMID: 30132679

Year	Number of Results
1993	1
1998	3
1999	1
2001	2
2003	2
2004	1
2005	2
2006	2
2007	2
2008	4
2009	2
2011	2
2012	3
2013	5
2014	6
2015	9
2016	12
2017	15
2018	28
2019	39
2020	41
2021	43
2022	20
2023	9
2024	0

1

Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.

Lyle L, Daver N. Lyle L, et al. Am J Manag Care. 2018 Aug;24(16 Suppl):S356-S365. Am J Manag Care. 2018. PMID: 30132679 Free article. Review.

2

Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.

Lee DJ, Zeidner JF. Lee DJ, et al. Expert Opin Investig Drugs. 2019 Nov;28(11):989-1001. doi: 10.1080/13543784.2019.1678583. Epub 2019 Oct 22. Expert Opin Investig Drugs. 2019. PMID: 31612739 Review.

3

Venetoclax-based therapies for acute myeloid leukemia.

Guerra VA, DiNardo C, Konopleva M. Guerra VA, et al. Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24. Best Pract Res Clin Haematol. 2019. PMID: 31203996 Free PMC article. Review.

4

Combined venetoclax and alvocidib in acute myeloid leukemia.

Bogenberger J, Whatcott C, Hansen N, Delman D, Shi CX, Kim W, Haws H, Soh K, Lee YS, Peterson P, Siddiqui-Jain A, Weitman S, Stewart K, Bearss D, Mesa R, Warner S, Tibes R. Bogenberger J, et al. Oncotarget. 2017 Nov 3;8(63):107206-107222. doi: 10.18632/oncotarget.22284. eCollection 2017 Dec 5. Oncotarget. 2017. PMID: 29291023 Free PMC article.

5

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.

Naqvi K, Konopleva M, Ravandi F. Naqvi K, et al. Expert Rev Hematol. 2017 Oct;10(10):863-874. doi: 10.1080/17474086.2017.1366852. Epub 2017 Aug 21. Expert Rev Hematol. 2017. PMID: 28799432 Review.

6

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.

Ikezoe T, Ando K, Onozawa M, Yamane T, Hosono N, Morita Y, Kiguchi T, Iwasaki H, Miyamoto T, Matsubara K, Sugimoto S, Miyazaki Y, Kizaki M, Akashi K. Ikezoe T, et al. Cancer Sci. 2022 Dec;113(12):4258-4266. doi: 10.1111/cas.15458. Epub 2022 Oct 10. Cancer Sci. 2022. PMID: 35689544 Free PMC article. Clinical Trial.

7

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.

Nishi R, Shigemi H, Negoro E, Okura M, Hosono N, Yamauchi T. Nishi R, et al. BMC Cancer. 2020 Oct 12;20(1):984. doi: 10.1186/s12885-020-07469-x. BMC Cancer. 2020. PMID: 33046037 Free PMC article.

8

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.

Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M. Lehmann C, et al. J Hematol Oncol. 2016 Jun 28;9(1):50. doi: 10.1186/s13045-016-0280-3. J Hematol Oncol. 2016. PMID: 27353420 Free PMC article.

9

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.

Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, Lee EM, Lock RB, Zuber J, Shortt J, Johnstone RW. Baker A, et al. Cancer Res. 2016 Mar 1;76(5):1158-69. doi: 10.1158/0008-5472.CAN-15-1070. Epub 2015 Dec 1. Cancer Res. 2016. PMID: 26627013

10

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia.

Tibes R, Bogenberger JM. Tibes R, et al. Front Oncol. 2019 Dec 12;9:1205. doi: 10.3389/fonc.2019.01205. eCollection 2019. Front Oncol. 2019. PMID: 31921615 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

228 results

Results by year